10:31 AM EST, 11/10/2025 (MT Newswires) -- Venus Concept ( VERO ) said Monday it secured a 510(k) clearance from the US Food and Drug Administration to market the Venus NOVA platform for non-invasive skin treatments.

The new platform is expected to provide clinics with access to real-time analytics and treatment insights for higher efficiency and profitability, Venus Concept ( VERO ) said.

Venus NOVA, supported by the Venus Jumpstart Program, will be available to US clients in December with a global launch planned throughout 2026, the company said.

Shares of Venus Concept ( VERO ) rose 36% in recent trading.

Price: 2.86, Change: +0.93, Percent Change: +48.19